Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Psoriasis symbols : AMGN save search
Leading Players Pfizer, AbbVie, and Novartis at the Forefront of Advancements in Plaque Psoriasis Treatment
Published: 2023-09-20 (Crawled : 22:00) - prnewswire.com
UCBJY | $63.0 11K
|
Manufacturing
|
| O: -0.79%
H: 0.0%
C: -1.26%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: -0.7%
H: 0.06%
C: -0.75%
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: -1.47%
H: 0.0%
C: 0.0%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: -0.04%
H: 0.76%
C: -0.16%
SNY | $46.05 -0.41% 940K
|
Health Technology
|
| O: -1.16%
H: 0.0%
C: 0.0%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.22%
H: 0.15%
C: -0.98%
psoriasis treatment novartis
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
BMY | $48.365 -0.3% 4.9M
|
Health Technology
|
| O: 0.01%
H: 0.75%
C: 0.18%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.1%
H: 0.71%
C: 0.62%
approval psoriasis treatment
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Published: 2023-01-27 (Crawled : 13:00) - biospace.com/
BMY | $48.365 -0.3% 4.9M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: -0.74%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.0%
H: 0.25%
C: -0.48%
treatment chmp psoriasis positive
Global Psoriasis Therapeutics Market Report to 2031 - Featuring Abbvie, Amgen, Bausch Health, LEO Pharma and Novan Among Others
Published: 2023-01-25 (Crawled : 21:00) - prnewswire.com
NVSEF | $93.6375 82K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
VTRS | $11.155 -1.46% 4.1M
|
Health Technology
|
| O: -0.69%
H: 0.87%
C: 0.69%
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: -1.97%
H: 0.11%
C: -1.25%
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: 0.36%
H: 0.34%
C: -0.85%
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: 1.91%
H: 3.28%
C: -0.23%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: 0.09%
H: 0.53%
C: -0.35%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.0%
H: 0.06%
C: -0.65%
leo pharma global report therapeutics psoriasis market
U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
Published: 2022-09-10 (Crawled : 08:20) - biospace.com/
BMY | $48.365 -0.3% 4.9M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $264.955 -0.21% 880K
|
Health Technology
| Email alert
Add to watchlist
treatment drug psoriasis food plague
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Published: 2021-12-01 (Crawled : 22:00) - biospace.com/
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: 3.7%
H: 3.74%
C: -0.91%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: 0.78%
H: 2.59%
C: 0.18%
psoriasis positive results phase 3 topline
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
Published: 2021-11-29 (Crawled : 12:30) - biospace.com/
BMY | $48.365 -0.3% 4.9M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -1.18%
H: 1.16%
C: 0.49%
psoriasis food treatment europe application drug plague
Global $53 Bn Psoriasis Drugs Markets 2021-2030: Biologic Drugs, Small-Molecule Systemic Drugs, Topical Therapies, TNF-Alpha, PDE4, & Interleukin Inhibitors, Oral, Parenteral, Topical
Published: 2021-06-04 (Crawled : 21:00) - prnewswire.com
LLY | $749.215 -0.21% 1.4M
|
Health Technology
| Email alert
Add to watchlist
AMGN | $264.955 -0.21% 880K
|
Health Technology
| Email alert
Add to watchlist
NVS | $92.99 -1.5% 990K
|
Health Technology
| Email alert
Add to watchlist
BHC | $8.595 -0.41% 880K
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.365 -0.3% 4.9M
|
Health Technology
| Email alert
Add to watchlist
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
| Email alert
Add to watchlist
GSK | $40.035 -1.15% 1.5M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $163.42 1.08% 2M
|
Health Technology
| Email alert
Add to watchlist
drug psoriasis therapy
FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis
Published: 2021-05-05 (Crawled : 14:15) - biospace.com/
BGNE S | $134.185 -3.05% 150K
|
Health Technology
|
| O: -0.5%
H: 3.2%
C: -1.07%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.43%
H: 1.5%
C: 1.24%
new drug fda drug psoriasis fda acceptance application plague
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Published: 2021-04-23 (Crawled : 18:00) - biospace.com/
BMY | $48.365 -0.3% 4.9M
|
Health Technology
|
| O: -0.03%
H: 0.95%
C: -0.44%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.03%
H: 1.24%
C: 0.8%
positive phase 3 psoriasis
Global Psoriasis Drugs Market to Reach $53,210.6 Million by 2030, says P&S Intelligence
Published: 2021-04-07 (Crawled : 08:00) - prnewswire.com
NVS | $92.99 -1.5% 990K
|
Health Technology
|
| O: 0.02%
H: 0.34%
C: -0.09%
JNJ | $145.405 -1.48% 7.6M
|
Health Technology
|
| O: 0.1%
H: 0.45%
C: 0.04%
GSK | $40.035 -1.15% 1.5M
|
Health Technology
|
| O: 0.58%
H: 0.28%
C: -0.47%
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: 0.05%
H: 0.15%
C: -0.32%
BMY | $48.365 -0.3% 4.9M
|
Health Technology
|
| O: 0.05%
H: 0.85%
C: 0.08%
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: -0.1%
H: 1.33%
C: 1.09%
ABBV | $163.42 1.08% 2M
|
Health Technology
|
| O: 0.14%
H: 0.57%
C: -0.3%
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.37%
H: 0.83%
C: -0.02%
drug psoriasis
Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis
Published: 2021-02-22 (Crawled : 14:12) - prnewswire.com
AMGN | $264.955 -0.21% 880K
|
Health Technology
|
| O: -0.59%
H: 1.51%
C: 0.49%
drug new drug psoriasis application plague
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
WISA 4 | $5.33 204.57% 190M
|
Electronic Technology
TPET | $0.5189 124.54% 38M
|
n/a
SXTC | $1.78 52.14% 33M
|
Health Technology
JAGX | $0.1771 49.07% 540M
|
Health Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
FNCH | $2.98 32.74% 400K
|
Professional, Scientific, and T...
PALI | $5.51 32.45% 28M
|
Manufacturing
VERO | $0.804 31.8% 110K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.